Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.68 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.68 |
| ▸ | TSHR | P16473 | 1/20 | 0.68 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.68 |
| ▸ | QPCT | Q16769 | 1/20 | 0.67 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.56 |
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17481128 | 0.90 | CYP3A4 (0.82) | CYP3A4CYP2D6TSHRCYP2C19QPCT | |
| SCHEMBL17285644 | 0.86 | QPCT (0.70) | CYP3A4CYP2D6TSHRCYP2C19QPCT | |
| SCHEMBL5036734 | 0.85 | CYP3A4 (0.64) | CYP3A4CYP2D6TSHRCYP2C19QPCT | |
| SCHEMBL31483846 | 0.84 | QPCT (0.83) | CYP3A4CYP2D6TSHRCYP2C19QPCT | |
| SCHEMBL13033285 | 0.84 | CYP3A4 (0.74) | CYP3A4CYP2D6TSHRCYP2C19QPCT | |
| SCHEMBL18381205 | 0.84 | CYP3A4 (0.74) | CYP3A4CYP2D6TSHRCYP2C19QPCT | |
| SCHEMBL17483163 | 0.84 | CYP3A4 (0.78) | CYP3A4CYP2D6TSHRCYP2C19QPCT | |
| SCHEMBL17481134 | 0.84 | CYP3A4 (0.78) | CYP3A4CYP2D6TSHRCYP2C19QPCT | |
| SCHEMBL25670592 | 0.83 | CYP3A4 (0.72) | CYP3A4CYP2D6TSHRCYP2C19QPCT | |
| SCHEMBL29419585 | 0.82 | CYP3A4 (0.76) | CYP3A4CYP2D6TSHRCYP2C19QPCT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8188239-B2 | Multivalent carriers of bi-specific antibodies | IMMUNOMEDICS, INC. (US) | 2012-05-29 | — | — | US | disclosed |
| US-20110229407-A1 | Alpha-Fetoprotein Immu31 Antibodies and Fusion Proteins and Methods of Use Thereof | IMMUNOMEDICS, INC. (US) | 2011-09-22 | — | — | US | disclosed |
| US-20110223645-A1 | Multivalent Carriers of Bi-Specific Antibodies | IMMUNOMEDICS, INC. (US) | 2011-09-15 | — | — | US | disclosed |
| US-7892547-B2 | Methods and compositions for administering therapeutic and diagnostic agents | IMMUNOMEDICS, INC. (US) | 2011-02-22 | — | — | US | disclosed |
| US-7820164-B2 | Chimeric, human and humanized anti-CSAP monoclonal antibodies | IMMUNOMEDICS, INC. (US) | 2010-10-26 | — | — | US | disclosed |
| US-7776311-B1 | Immunological reagents for therapeutic use, in radioimmunotherapy (RAIT), and diagnostic use, in radioimmunodetection (RAID) and magnetic resonance imaging; conjugated drug as antiinflammatory, or anticarcinogenic agents; drug targets; tissue-targeted therapy | IMMUNOMEDICS, INC. (US) | 2010-08-17 | — | — | US | disclosed |
| US-20100202961-A1 | D-AMINO ACID PEPTIDES | IMMUNOMEDICS, INC. | 2010-08-12 | — | — | US | disclosed |
| US-20100158803-A1 | Production and Use of Novel Peptide-Based Agents for Use with Bi-Specific Antibodies | IMMUNOMEDICS, INC. (US) | 2010-06-24 | — | — | US | disclosed |
| US-20100158802-A1 | Chimeric, Human and Humanized Anti-CSAP Monoclonal Antibodies | IMMUNOMEDICS, INC. (US) | 2010-06-24 | — | — | US | disclosed |
| US-7666415-B2 | Production and use of novel peptide-based agents for use with bi-specific antibodies | IMMUNOMEDICS, INC. (US) | 2010-02-23 | — | — | US | disclosed |
| US-7521416-B2 | D-amino acid peptides | IMMUNOMEDICS, INC. (US) | 2009-04-21 | — | — | US | disclosed |
| US-7501498-B2 | Alpha-fetoprotein Immu31 antibodies and fusion proteins | IMMUNOMEDICS, INC. (US) | 2009-03-10 | — | — | US | disclosed |
| US-20080293921-A1 | Production and Use of Novel Peptide-Based Agents for Use with Bi-Specific Antibodies | IMMUNOMEDICS, INC. (US) | 2008-11-27 | — | — | US | disclosed |
| US-7429381-B2 | Production and use of novel peptide-based agents for use with bi-specific antibodies | IMMUNOMEDICS, INC. (US) | 2008-09-30 | — | — | US | disclosed |
| US-20080219920-A1 | Chimeric, Human and Humanized Anti-CSAP Monoclonal Antibodies | IMMUNOMEDICS, INC. | 2008-09-11 | — | — | US | disclosed |
| US-7414121-B2 | Chimeric, human and humanized anti-CSAp monoclonal antibodies | IMMUNOMEDICS, INC. (US) | 2008-08-19 | — | — | US | disclosed |
| US-20080146784-A1 | Alpha-Fetoprotein Immu31 Antibodies and Fusion Proteins and Methods of Use Thereof | IMMUNOMEDICS, INC. (US) | 2008-06-19 | — | — | US | disclosed |
| US-7387772-B1 | Chimeric, human and humanized anti-CSAP monoclonal antibodies | IMMUNIMEDICS, INC. (US) | 2008-06-17 | — | — | US | disclosed |
| US-20070183970-A1 | Chimeric, human and humanized anti-granulocyte antibodies and methods of use | IMMUNOMEDICS, INC. | 2007-08-09 | — | — | US | disclosed |
| US-20070142296-A1 | D-amino acid peptides | IMMUNOMEDICS, INC. | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146784-A1 | Alpha-Fetoprotein Immu31 Antibodies and Fusion Proteins and Methods of Use Thereof | INHA, HDGF, IGSF11 | CYP3A4 3808/4885CYP2D6 4049/4885TSHR 1778/4885 |
| US-20100158802-A1 | Chimeric, Human and Humanized Anti-CSAP Monoclonal Antibodies | CHP1, CLSPN, CYTH3 | CYP3A4 2408/4885CYP2D6 2480/4885TSHR 4399/4885 |
| US-20070142296-A1 | D-amino acid peptides | DAO, NRDC, ARGLU1 | CYP3A4 4204/4885CYP2D6 2633/4885TSHR 88/4885 |
| US-20110229407-A1 | Alpha-Fetoprotein Immu31 Antibodies and Fusion Proteins and Methods of Use Thereof | INHA, HDGF, IGSF11 | CYP3A4 3808/4885CYP2D6 4049/4885TSHR 1778/4885 |
| US-20070183970-A1 | Chimeric, human and humanized anti-granulocyte antibodies and methods of use | CSF3R, CCR3, FCGR3B | CYP3A4 4390/4885CYP2D6 4018/4885TSHR 2795/4885 |
| US-20080219920-A1 | Chimeric, Human and Humanized Anti-CSAP Monoclonal Antibodies | CHP1, CLSPN, CYTH3 | CYP3A4 2408/4885CYP2D6 2480/4885TSHR 4399/4885 |
| US-20080293921-A1 | Production and Use of Novel Peptide-Based Agents for Use with Bi-Specific Antibodies | HRH3, BSG, HRH4 | CYP3A4 3351/4885CYP2D6 1426/4885TSHR 2012/4885 |
| US-20100202961-A1 | D-AMINO ACID PEPTIDES | ARGLU1, APLNR, NPBWR1 | CYP3A4 4383/4885CYP2D6 2942/4885TSHR 93/4885 |
| US-20110223645-A1 | Multivalent Carriers of Bi-Specific Antibodies | FCGR3B, FCGR2A, FCGR1A | CYP3A4 4501/4885CYP2D6 4022/4885TSHR 1184/4885 |
| US-20100158803-A1 | Production and Use of Novel Peptide-Based Agents for Use with Bi-Specific Antibodies | HRH3, BSG, HRH4 | CYP3A4 4249/4885CYP2D6 2619/4885TSHR 1755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.